Precision BioSciences (NASDAQ:DTIL) & Allogene Therapeutics (NASDAQ:ALLO) Critical Comparison

Allogene Therapeutics (NASDAQ:ALLOGet Free Report) and Precision BioSciences (NASDAQ:DTILGet Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Profitability

This table compares Allogene Therapeutics and Precision BioSciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Allogene Therapeutics -223,139.98% -52.13% -41.29%
Precision BioSciences 11.48% -23.69% -6.98%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Allogene Therapeutics and Precision BioSciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allogene Therapeutics 0 1 9 0 2.90
Precision BioSciences 0 0 2 0 3.00

Allogene Therapeutics presently has a consensus target price of $9.73, indicating a potential upside of 350.62%. Precision BioSciences has a consensus target price of $39.50, indicating a potential upside of 742.22%. Given Precision BioSciences’ stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Allogene Therapeutics.

Volatility & Risk

Allogene Therapeutics has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Insider & Institutional Ownership

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 4.0% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Allogene Therapeutics and Precision BioSciences”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allogene Therapeutics $43,000.00 10,532.36 -$327.27 million ($1.56) -1.38
Precision BioSciences $75.10 million 0.48 -$61.32 million $0.06 78.17

Precision BioSciences has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Summary

Precision BioSciences beats Allogene Therapeutics on 10 of the 14 factors compared between the two stocks.

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

About Precision BioSciences

(Get Free Report)

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.